BusinessPostCorner.com
No Result
View All Result
Friday, July 4, 2025
  • Home
  • Business
  • Finance
  • Accounting
  • Tax
  • Management
  • Marketing
  • Crypto News
  • Human Resources
BusinessPostCorner.com
  • Home
  • Business
  • Finance
  • Accounting
  • Tax
  • Management
  • Marketing
  • Crypto News
  • Human Resources
No Result
View All Result
BusinessPostCorner.com
No Result
View All Result

Pfizer shares tumble on weak forecast for 2024 revenues

December 13, 2023
in Finance
Reading Time: 2 mins read
A A
0
Pfizer shares tumble on weak forecast for 2024 revenues
ShareShareShareShareShare

Unlock the Editor’s Digest for free

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.

Pfizer shares tumbled more than 7 per cent after the US drugmaker forecast 2024 revenues that were below consensus estimates, as the company attempts to chart a future for growth without blockbuster Covid-19 products.

The company said on Wednesday it expected 2024 revenues to fall to between $58.5bn and $61.5bn. An average of analyst estimates compiled by Reuters had seen revenues of $63.17bn for the same period.

When it released third-quarter earnings in October, Pfizer said it expected 2023 revenues to fall to between $58bn and $61bn, down from a previously issued guidance, in May this year, of $67bn to $71bn.

The drugmaker on Wednesday said it also expected adjusted earnings per share to come in at between $2.05 and $2.25, below Reuters estimates of $3.16 per share.

After raking in billions of dollars through sales of the Covid vaccine it co-developed with Germany’s BioNTech during the pandemic and seeing share prices surge, Pfizer has struggled to reorientate its pipeline and to reassure investors about its growth potential.

“We are acutely aware that all these uncertainties are making it difficult to project the future revenues of Pfizer — and are also affecting our stock price,” Albert Bourla, the company’s chief executive, said on a recent earnings call.

The same concerns have plagued other drugmakers whose sales surged during the pandemic, such as Moderna and Pfizer’s partner BioNTech.

Recommended

In response to these concerns, Pfizer initiated a significant cost-cutting programme, worth at least $4bn.

But an increase of $500mn in cost cutting announced on Wednesday was still not enough to please investors. New York-listed shares lost 7.3 per cent before the open, after losing more than 44 per cent this year.

To make up for the shortfall in its pipeline, the US drugmaker earlier this year announced plans to buy Seagen, an oncology drugmaker, for $43bn; a deal Pfizer said it expected to close on Thursday.

Credit: Source link

ShareTweetSendPinShare
Previous Post

a16z and Founders Fund lead $13.5 million round for crypto onboarding startup Dynamic Labs

Next Post

Elon Musk's Tesla recalls two million cars over Autopilot defect

Next Post
Elon Musk's Tesla recalls two million cars over Autopilot defect

Elon Musk's Tesla recalls two million cars over Autopilot defect

‘Massive’ investment in R&D leads China’s Honor to launch world’s thinnest foldable phone

‘Massive’ investment in R&D leads China’s Honor to launch world’s thinnest foldable phone

July 3, 2025
Trump says July 4 tax-cut bill deadline isn’t the ‘end all’ date

Trump says July 4 tax-cut bill deadline isn’t the ‘end all’ date

June 27, 2025
Benefits U-turn raises questions about Labour’s long-term plan

Benefits U-turn raises questions about Labour’s long-term plan

June 27, 2025
Citroen owners left stranded over airbag safety risk

Citroen owners left stranded over airbag safety risk

July 3, 2025
Trump Family Rakes In 0M+ From Crypto: Meme coin Windfall, Token Sales, and a 20% Bitcoin Stake

Trump Family Rakes In $620M+ From Crypto: Meme coin Windfall, Token Sales, and a 20% Bitcoin Stake

July 2, 2025
PwC to cut 175 junior auditors amid slowdown

PwC to cut 175 junior auditors amid slowdown

June 28, 2025
BusinessPostCorner.com

BusinessPostCorner.com is an online news portal that aims to share the latest news about following topics: Accounting, Tax, Business, Finance, Crypto, Management, Human resources and Marketing. Feel free to get in touch with us!

Recent News

Solo Bitcoin Miner Strikes Gold, Nets Nearly 0,000 from Single Block

Solo Bitcoin Miner Strikes Gold, Nets Nearly $350,000 from Single Block

July 4, 2025
London IPO fundraising falls to 30-year low

London IPO fundraising falls to 30-year low

July 4, 2025

Our Newsletter!

Loading
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • DMCA

© 2023 businesspostcorner.com - All Rights Reserved!

No Result
View All Result
  • Home
  • Business
  • Finance
  • Accounting
  • Tax
  • Management
  • Marketing
  • Crypto News
  • Human Resources

© 2023 businesspostcorner.com - All Rights Reserved!